The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
News|Podcasts|November 27, 2023
Biomarker Testing and Targeted Therapy in NSCLC: Review and Update (Podcast)
Expert Derek Lyle, MD, provides an in-depth overview of biomarker testing and targeted therapy in the current landscape of non–small cell lung cancer management.
Advertisement
Advertisement
Related to this article
Moh’d Khushman, MD, discusses INCA33890’s mechanism of action, phase 1 safety and efficacy data, and the design of NEXERA-303 in MSS colorectal cancer.
The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.
Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
Researchers in a Mayo Clinic-led study have shown how to detect a broad range of DNA mutations in noncancerous human tissues and across the genome.
Nunnery and Bond discuss how patients and advocates can navigate second opinions, mental health support, and the long-term effects of cancer treatment.
The CHMP opinion is backed by phase 3 MonumenTAL-3 data evaluating talquetamab plus daratumumab in relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 10/11
2
VOLGA, DASL-HiCaP Data Highlight Key Genitourinary Cancer Presentations Arriving at ESMO 2026
3
Alternative Cemiplimab Dosing Strategy Receives CHMP Recommendation in Multiple Cancer Types
4
CHMP Recommends Approval of Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
5